裏格爾製藥 RIGL 深 滬
等待開盤 06-25 09:30:00 美东时间
36.55
+0.940
+2.64%
華盛通- 最 高37.01
- 今 開36.23
- 成交量 29.18万股
- 最 低 35.823
- 昨 收 35.61
- 總市值 67.63万
- 52周最高 52.24
- 市盈率 靜 1.88
- 換手率 1577.18%
- 52周最低 18.24
- 委 比 -43.13%
- 總股本 1.85万
- 歷史最高 114.40
- 量 比 0.59
- 振 幅 3.33%
- 歷史最低 6.40
- 每 手 1
- 風險率 7.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antit...
06-17 04:04
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, t...
06-17 04:01
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
05-22 18:51
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
05-13 02:38
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license agreement
05-12 19:15
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
05-08 05:53
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.
05-06 06:23
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Rigel Pharmaceuticals (NASDAQ:RIGL) released first-quarter financial results an...
05-06 05:20
